This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Septic Shock
and you are
over 18
years old
The primary goal of this phase is to monitor the long-term effects.
The treatment is already on the market.
Show me locations

The purpose

The purpose is to demonstrate that vasoreactivity of patients with septic shock evaluated with dose-response curve is diminished in septic shock and ameliorated by activated protein C (APC). This amelioration is correlated to decrease of inflammation, decrease of reactive oxygen species (ROS) markers and increase of circulating catecholamines.

Provided treatments

  • Drug: Recombinant Activated Protein C
  • Device: Near-infrared spectroscopy (NIRS)
  • Drug: Phenylephrine
  • Biological: Blood sample

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT02885168. The sponsor of the trial is Central Hospital, Nancy, France and it is looking for 30 volunteers for the current phase.
Official trial title:
Modulation of Vasoreactivity in Septic Shock: Impact of Recombinant Protein C